First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

Phase 1 Completed 16 enrolled YourChoice Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindOther

Summary

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.

Timeline

Start: 2023-12-20
Primary completion: 2024-06-18
Completion: 2024-06-18

Publications

Mannowetz N, McCallum SW, Sidhu S, Mena KH, Ruby EP, Castro-Santamaria R, Dodds E, Henderson D, Whitaker G, Wright H, Beaudoin S, Bakshi A. Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529. Commun Med (Lond). 2025 Jul 22;5(1):279. doi: 10.1038/s43856-025-01004-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	YCT-529	Small molecule	10 mg	Oral
Comparator	YCT-529	Small molecule	30 mg	Oral
Comparator	YCT-529	Small molecule	90 mg	Oral
Comparator	YCT-529	Small molecule	200 mg	Oral

Indications

No indication recorded.